Relmada Therapeutics, INC 10-Q quarterly reports

Relmada Therapeutics, Inc. filed its quarterly report for the period ending June 30, 2026, detailing continued investment in research and development for its lead candidates, NDV-01 and sepranolone, alongside significant cash reserves.

Relmada Therapeutics reports significant progress in its clinical pipeline with NDV-01 and sepranolone, bolstered by a substantial capital raise, while navigating operational expenses.

Relmada Therapeutics reports a strategic pipeline overhaul, including two program terminations and the acquisition of two new drug candidates, alongside a significant $94 million capital raise to fund operations for the next 12 months.

Relmada Therapeutics reports a reduced net loss in Q2 2025, driven by strategic pipeline changes including new acquisitions and program terminations, but faces significant liquidity challenges and a Nasdaq compliance extension.

Relmada Therapeutics reports a net loss for Q1 2025 and provides updates on its strategic review, pipeline diversification, and key upcoming milestones.

Relmada Therapeutics reported its Q3 2024 financial results, highlighting ongoing clinical trials and a net loss, while also expressing substantial doubt about its ability to continue as a going concern.

Relmada Therapeutics reported a net loss of $39.6 million for the first six months of 2024, while continuing to advance its clinical programs for esmethadone and psilocybin.

Relmada Therapeutics reported a net loss of $21.8 million for the first quarter of 2024, while continuing to advance its clinical programs for esmethadone and psilocybin.